Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist

International Journal of Antimicrobial Agents

Volumn 29, Issue 5, 2007, Pages 494-500

  Esposito, Silvano ^a   Leone, Sebastiano ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Antibiotic therapy; Appropriate and inappropriate therapy; ICU infections; Infectious disease specialist

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEPHALOSPORIN; CHLORAMPHENICOL; COLISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FOSFOMYCIN; IMIPENEM; LINEZOLID; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; DEVICE INFECTION; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; INFECTION RISK; MEDICAL SPECIALIST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PNEUMONIA; PRIORITY JOURNAL; SHORT SURVEY; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-INFECTIVE AGENTS; BACTERIA; BETA-LACTAMASES; CROSS INFECTION; HUMANS; INFECTION CONTROL; INFECTION CONTROL PRACTITIONERS; INTENSIVE CARE UNITS; METHICILLIN RESISTANCE; VANCOMYCIN RESISTANCE;

EID: 34147162424     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.10.017     Document Type: Short Survey

References (58)

1. Weinstein R.A. Nosocomial infection update. Emerg Infect Dis 4 (1998) 416-420
2. Jarvis W.R. Infection control and changing health-care delivery systems. Emerg Infect Dis 7 (2001) 170-173
3. Eggimann P., and Pittet D. Infection control in the ICU. Chest 120 (2001) 2059-2093
4. Richards M.J., Edwards J.R., Culver D.H., and Gaynes R.P. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 21 (2000) 510-515
5. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992-June 2004. Am J Infect Control 2004;32:470-85.
6. Jevons M.P. "Celbenin-resistant" staphylococci. BMJ 1 (1961) 124-125
7. Diekema D.J., BootsMiller B.J., Vaughn T.E., et al. Antimicrobial resistance trends and outbreak frequency in United States Hospitals. Clin Infect Dis 38 (2004) 78-85
8. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., and Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36 (2003) 53-59
9. Whitby M., McLaws M.L., and Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 175 (2001) 264-267
10. Melzer M., Eykyn Sj., Gransden W.R., and Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 37 (2003) 1453-1460
11. Zahar J.R., Clech C., Tafflet M., et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?. Clin Infect Dis 41 (2005) 1224-1231
12. Cepeda J., Hayman S., Whitehouse T., et al. Teicoplanin resistance in methicillin-resistant Staphylococcus aureus in an intensive care unit. J Antimicrob Chemother 52 (2003) 533-534
13. Goldstein F.W., and Kitzis M.D. Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin Microbiol Infect 9 (2003) 761-765
14. Nathwani D., and Tillotson G.S. Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era?. Int J Antimicrob Agent 21 (2003) 521-524
15. Noskin G.A., Siddiqui F., Stosor V., Hacek D., and Peterson L.R. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 43 (1999) 2059-2062
16. Rubinstein E., Cammarata S., Oliphant T., and Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32 (2001) 402-412
17. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., and Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34 (2002) 1481-1490
18. Fagon J.Y., Patrick H., Haas D.W., et al. Treatment of gram-positive nosocomial pneumonia, prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 161 (2000) 753-762
19. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., and Jones R.N. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 52 (2005) 185-193
20. Carpenter C.F., and Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38 (2004) 994-1000
21. Johnson A.P., Mushtaq S., Warner M., and Livermore D.M. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int J Antimicrob Agent 24 (2003) 315-319
22. Clark N.C., Cooksey R.C., Hill B.C., Swenson J.M., and Tenover F.C. Characterization of glycopeptide-resistant enterococci from US hospitals. Antimicrob Agents Chemother 37 (1993) 2311-2317
23. Bhavnani S.M., Drake J.A., Forrest A., et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 36 (2000) 145-158
24. Garbutt J.M., Ventrapragada M., Littenberg B., and Mundy L.M. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 30 (2000) 466-472
25. DiazGranados C.A., Zimmer S.M., Klein M., and Jernigan J.A. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 41 (2005) 327-333
26. Kauffman C.A. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 51 (2003) 23-30
27. Linden P.K., Moellering Jr. R.C., Wood C.A., et al. Treatment of vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin. Clin Infect Dis 33 (2001) 1816-1823
28. Eliopoulos G.M., Wennersten C.B., Gold H.S., and Moellering R.C. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 40 (1996) 1745-1747
29. Chien J.W., Kucia M.L., and Salata R.A. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 30 (2000) 146-151
30. Sader H.S., Streit J.M., Fritsche T.R., and Jones R.N. Antimicrobial activity of daptomycin against multidrug-resistant Gram positive strains collected worldwide. Diagn Microbiol Infect Dis 50 (2004) 201-204
31. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agent 25 (2005) 185-192
32. Turner P.J. Extended-spectrum β-lactamases. Clin Infect Dis 41 (2005) 273-275
33. Lautenbach E., Patel J.B., Bilker W.B., Edelstein P.H., and Fishman N.O. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32 (2001) 1162-1171
34. Ariffin H., Navaratnam P., Mohamed M., et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 4 (2000) 21-25
35. Kim Y.K., Pai H., Lee H.J., et al. Bloodstream infections by extended spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 46 (2002) 1481-1491
36. Paterson D.L., Ko W.C., Von Gottberg A., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39 (2001) 2206-2212
37. Paterson D.L., Ko W.C., and Von Gottberg A. Therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 39 (2003) 31-37
38. Kang C.I., Kim S.H., Park W.B., et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48 (2004) 4574-4581
39. Watanabe M., Iyobe S., Inoue M., and Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 35 (1991) 147-151
40. Fritsche T.R., Sader H.S., Toleman M.A., Walsh T.R., and Jones R.N. Emerging metallo-β-lactamase-mediated resistances: a summary report from the Worldwide SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 41 (2005) 276-278
41. Karabinis A., Paramythiotou E., Mylona-Petropoulo D., et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis 38 (2004) 7-9
42. Garnacho-Montero J., Ortiz-Leyba C., Jimenez-Jimenez F.J., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36 (2003) 1111-1118
43. Pachón-Ibánez M.E., Jiménez-Mejías M.E., Pichardo C., Llanos A.C., and Pachón J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii. Antimicrob Agents Chemother 48 (2004) 4479-4481
44. Alvarez-Lerma F. Modification of empiric antibiotic treatment antimicrobial treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 22 (1996) 387-394
45. Leibovici L., Shraga I., Drucker M., Konigsberger H., Samra Z., and Pitlik S.D. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 244 (1998) 379-386
46. Luna C.M., Vujacich P., Niedeman M.S., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111 (1997) 676-685
47. Kollef M.H. The importance of appropriate initial antibiotic therapy for hospital-acquired infections. Am J Med 115 (2003) 1582-1584
48. Rello J., Gallego M., Mariscal D., Sonora R., and Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 156 (1997) 196-200
49. MacArthur R.D., Miller M., Albertson T., et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS Trial. Clin Infect Dis 38 (2004) 284-288
50. Behrendt G., Schneider S., Brodt H.R., Just-Nubling G., and Shah P.M. Influence of antimicrobial treatment on mortality in septicemia. J Chemother 11 (1999) 179-186
51. Rubin R.J., Harrington C.A., Poon A., Dietrich K., Greene J.A., and Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 5 (1999) 9-17
52. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
53. Byl B., Clevenbergh P., Jacobs F., et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 29 (1999) 60-66
54. Fowler V.G., Sanders L.L., Sexton D.J., et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious disease specialist: experience with 244 patients. Clin Infect Dis 27 (1998) 478-486
55. Borer A., Gilad J., and Meydan N. Impact of regular attendance by infectious disease specialists on the management of hospitalised adults with community-acquired febrile syndromes. Clin Microbiol Infect 10 (2004) 911-916
56. Fluckiger U., Zimmmerli W., Sax H., et al. Clinical impact of an infectious disease service on the management of bloodstream infection. Eur J Clin Microbiol Infect Dis 19 (2000) 493-500
57. Lemmen S.W., Becker G., Frank U., and Daschner F.D. Influence of an infectious disease consulting service on quality and costs of antibiotic prescriptions in a university hospital. Scand J Infect Dis 33 (2001) 219-221
58. Lemmen S.W., Hafner H., Kotterik S., Lutticken R., and Topper R. Influence of an infectious disease service on antibiotic prescription behaviour and selection of multiresistant pathogens. Infection 28 (2000) 384-387